Axogen has been through a remarkable share price journey in recent years, which puts a spotlight on what investors are really paying for today. The question now is how well the current market value lines up with the cash flows that the business can generate over time.
- Over the past 3 years, Axogen has delivered a very large share price gain of roughly 7x, so recent buyers are effectively paying prices shaped by that run and not by a flat trading history.
- The business focuses on nerve repair solutions, so expectations around how efficiently it can turn that specialty into durable free cash flow may matter more than headline revenue growth when you think about intrinsic value.
- What if you looked at Axogen through its sales instead? See why Axogen's 8.3x P/S tells a different valuation story.
For investors, the debate is whether Axogen's current share price is adequately supported by the cash flows implied by its intrinsic value estimate using the Discounted Cash Flow (DCF) approach.
If you want to test the same cash flow question that hangs over Axogen against a broader set of stocks, take a look at 33 high quality undervalued stocks.
Is Axogen a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model here looks at what Axogen might return to shareholders in cash over time and then pulls that back to today. On the latest twelve month numbers, Axogen is generating roughly $6.8 million of free cash flow, so the current $35.63 share price is being weighed against a business that is already throwing off some cash rather than just a concept.
Where this DCF gets interesting is the projected ramp in free cash flow, which moves from single digit millions today to tens of millions per year within the next decade and assumes that growth gradually cools rather than staying aggressive. That profile suits a specialist in nerve repair solutions, where investors are often focused on the path to durable cash generation more than headline sales. The result is a set of cash flow projections that put Axogen's estimated intrinsic value meaningfully above the current share price, which is the gap this model is flagging for you to explore further. Find out what Axogen could be worth using our Discounted Cash Flow (DCF) estimate.
The Axogen Narrative: What Would Justify Today's Price?
Narratives for Axogen pick up where the valuation puzzle leaves off, explaining which paths for growth, profitability and earnings would need to occur for the stock to be worth meaningfully more or less than today's price on Simply Wall St's Community page. Instead of a single output from a ratio or model, Narratives describe the future assumptions behind that figure so you can watch how real world developments compare to it over time.
One of the top community narratives on Axogen: 33% undervalued
"Upcoming FDA Biologics License Application approval for Avance Nerve Graft in September 2025 is expected to secure 12 years of market exclusivity..."
Discover why this Narrative puts Axogen at 33% undervalued.
An unresolved piece of the Axogen story
Cash flow models only go so far when the real-world outcome also depends on who is steering Axogen, how they are rewarded, and whether those incentives truly align with your interests. See who runs Axogen and how they are paid.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com